Navigation Links
Meditation therapy for rheumatoid arthritis patients
Date:9/27/2007

remained under their rheumatologists care and continued to take their routine medications throughout the study.

Through random assignment, 31 of the participants received intensive MBSR therapy, starting with an 8-week training course followed by a 4-month maintenance program. The remaining 32 participants were designated to a waitlist, agreeing to attend assessment sessions in exchange for free MBSR training after the studys end. At baseline, and again at 2 months and 6 months into the study, both groups of participants underwent psychological and rheumatological examinations. To evaluate depressive symptoms and psychological distress, researchers used the Symptom Checklist-90-Revised, a self-report questionnaire widely recognized for its reliability and validity. Overall well-being was measured by the Psychological Well-Being Scales, comprised of questions designed to gauge positive outlook and approach to coping with difficulties. RA disease status was assessed by the Disease Activity Score in 28 joints (DAS-28).

Researchers compared scores of psychological and physical disease symptoms among MBSR participants with those among controls. Overwhelming, MBSR students embraced the program and kept up their mindfulness practice throughout the followup period. After 2 months, both groups showed improvements in depressive, psychological, and emotional symptoms, with no significant benefits attributed to MBSR. By 6 months, however, gains in the control group had largely disappeared, while MBSR participants maintained or improved further in psychological outcomes. By the culmination of the study, the MBSR group achieved a significant 35 percent reduction in psychological distress. Despite this dramatic improvement, the therapy had no impact on RA disease activity, measured by the DAS-28, which takes into account number of tender or swollen joints, a blood measure of inflammation, and the patients own report of diseas
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Fight Heart disease and Pain with Meditation
2. Meditation relieves stress
3. Meditation relieves stress
4. Meditation Works Medically
5. Meditation may reduce stress and help you live longer
6. Meditation Maintains And Thickens The Grey Matter Of The Brain
7. Meditation may Improve Cardiac Risk Factors in Patients with Coronary Heart Disease
8. Yoga and Meditation Comes in Aid of Iraqis to Rid of Trauma
9. Pain Tolerance Improved By Transcendental Meditation
10. Yoga and Meditation May be Helpful to Combat Chikungunya
11. Transcendental Meditation To The Rescue of Cardiac Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 1Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 1Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 7Stroke Damage Is Less in Rats Given Opioids 49194 1